Docket No. G. JAN-2 7 2003 6 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application for:

Susan Schiavi, et al.

Serial No.: 09/909,775

Filing Date: July 19, 2001

For: PHOSPHATONIN-RELATED GENE AND METHODS OF USE THEREOF

Examiner: Gibbs, Terra C.

Group Art Unit: 1635

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In accordance with 37 C.F.R. § 1.56, the reference listed on the attached form PTO-1449a is being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. The Examiner is requested to make these documents of record.

	This Supplemental Information Disclosure Statement is submitted:
	With the new patent application submitted herewith (37 C.F.R. § 1.97(a)).
	Within three months of the application filing date or before receipt of a first Office
	Action on the merits; accordingly, no fee or separate requirements are required.
×	Before the mailing date of the first Office Action on the merits. In the event, however
	that an Office Action has crossed in the mail with this Supplemental Information
	Disclosure Statement, the Commissioner is hereby authorized to charge Deposit
	Account No. 50-2518 for any fees required pursuant to 37 C.F.R. §§ 1.17(p) or
	1.176)(1)

	After receipt of a first Office Action on the merits but before a final Office Action or
	Notice of Allowance. A fee is required. The Commissioner is hereby authorized to
	charge Deposit Account No. 50-2518 for any fees required pursuant to 37 C.F.R.
	§§ 1.17(p) or 1.17(i)(1).
	After receipt of a final Office Action or Notice of Allowance, but before payment of
	the issue fee. Accordingly, a Certification under 37 C.F.R. § 1.97(e) is provided
	herein. The Commissioner is hereby authorized to charge Deposit Account
	No. 50-2518 for any fees required pursuant to 37 C.F.R. §§ 1.17(p) or 1.17(i)(1).
	The undersigned certifies that:
	Each item of information contained in the Information Disclosure Statement was first
	cited in any communication mailed from a foreign patent office in a counterpart
	foreign application not more than three months prior to the filing of this information
	disclosure statement.
	No item of information contained in this information disclosure statement was cited in
	a communication mailed from a foreign patent office in a counterpart foreign
	application or, to the knowledge of the undersigned after making reasonable inquiry,
	was known to any individual designated in 37 C.F.R. § 1.56(c) more than three
	months prior to the filing of this Information Disclosure Statement.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

This Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the U.S. Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 50-2518** referencing billing number 2019442-2194427201. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Registration No. 34,202

Bingham McCutchen LLP

Formerly McCutchen Doyle Brown & Enersen LLP

Three Embarcadero Center, Suite 1800 San Francisco, California 94111-4067

Telephone: (650) 849-4950 Facsimile: (650) 849-4800